Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418727 · ClinicalTrials.gov registry record · Phase 2
Dry Eye Disease Study With Brimonidine
A Phase 2 study, sponsored by Ocugen.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT03418727 is a Phase 2 study that has completed, run by Ocugen. The registered enrollment target is 84 participants.
The verdict
NCT03418727, a Phase 2 study, has completed, sponsored by Ocugen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
Interventions
- DRUG Brimonidine
- DRUG Brimonidine Mono Therapy
- DRUG sodium carboxymethylcellulose
- DRUG Corticosteroid Eye Drop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418727
The ClinicalTrials.gov registry entry for NCT03418727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocugen, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Brimonidine is the first listed.
NCT03418727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03418727 about?
NCT03418727 is a clinical study titled "Dry Eye Disease Study With Brimonidine". To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
What is the current status of trial NCT03418727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-09-06. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT03418727?
The interventions under investigation include: Brimonidine (DRUG), Brimonidine Mono Therapy (DRUG), sodium carboxymethylcellulose (DRUG), Corticosteroid Eye Drop (DRUG).
Who is sponsoring clinical trial NCT03418727?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.